Determining sex and reproductive status of rodents

The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The most current edition is made available. For access to an earlier edition, if available for this title, please contact the Oklahoma State University Library Archives by email at [email protected] or by phone at 405-744-6311

Managing for small mammal diversity

The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The most current edition is made available. For access to an earlier edition, if available for this title, please contact the Oklahoma State University Library Archives by email at [email protected] or by phone at 405-744-6311

Robert James Baker (1942-2018), Obituary

First paragraph: On 30 March 2018, the science of mammalogy and the American Society of Mammalogists lost one of the most influential figures of the last half-century. Robert James Baker died quietly at his home in Lubbock, Texas (Fig. 1). He was born on 8 April 1942 to James Simeon Baker and Laura Cooper in Warren, Arkansas. His father was killed during World War II and his mother remarried, resulting in his growing up with six half-siblings. According to Robert’s autobiography in Going afield (330—number refers to specific publication in “Bibliography”), he spent a good deal of his youth with his grandparents on a 100-acre farm in the West Gulf Coastal Plain of southeastern Arkansas. He identified his maternal grandmother, “Grandma Rosie,” as his best friend and his greatest influence during these years. His marriage to Jean Joyner on 19 August 1961 ended in divorce in 1975, but the marriage resulted in a daughter, April Baker-Padilla, and two grandchildren, Jason Baker and Faith Padilla. Robert was married to his wife of 39 years, Laura Kyle (M.D.), on 28 May 1978 in Lubbock. Their son, Robert Kyle Baker, preceded his father in death, which was a tragedy from which neither Robert nor Laura ever completely recovered

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

Background: Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome. Methods: In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0·9% saline via the extraventricular drain. The treating physician, clinical research staff, and participants were masked to treatment assignment. CT scans were obtained every 24 h throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 days per central adjudication by blinded evaluators. This study is registered with ClinicalTrials.gov, NCT00784134. Findings: Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group. 180-day follow-up data were available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. The primary efficacy outcome was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1·06 [95% CI 0·88–1·28; p=0·554]). A difference of 3·5% (RR 1·08 [95% CI 0·90–1·29], p=0·420) was found after adjustment for intraventricular haemorrhage size and thalamic intracerebral haemorrhage. At 180 days, the treatment group had lower case fatality (46 [18%] vs saline 73 [29%], hazard ratio 0·60 [95% CI 0·41–0·86], p=0·006), but a greater proportion with mRS 5 (42 [17%] vs 21 [9%]; RR 1·99 [95% CI 1·22–3·26], p=0·007). Ventriculitis (17 [7%] alteplase vs 31 [12%] saline; RR 0·55 [95% CI 0·31–0·97], p=0·048) and serious adverse events (114 [46%] alteplase vs 151 [60%] saline; RR 0·76 [95% CI 0·64–0·90], p=0·002) were less frequent with alteplase treatment. Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1·21 [95% CI 0·37–3·91], p=0·771) was similar. Interpretation: In patients with intraventricular haemorrhage and a routine extraventricular drain, irrigation with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with irrigation with saline. Protocol-based use of alteplase with extraventricular drain seems safe. Future investigation is needed to determine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produces gains in functional status

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

Acute stroke due to supratentorial intracerebral haemorrhage is associated with high morbidity and mortality. Open craniotomy haematoma evacuation has not been found to have any benefit in large randomised trials. We assessed whether minimally invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot size to 15 mL or less, would improve functional outcome in patients with intracerebral haemorrhage. MISTIE III was an open-label, blinded endpoint, phase 3 trial done at 78 hospitals in the USA, Canada, Europe, Australia, and Asia. We enrolled patients aged 18 years or older with spontaneous, non-traumatic, supratentorial intracerebral haemorrhage of 30 mL or more. We used a computer-generated number sequence with a block size of four or six to centrally randomise patients to image-guided MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses) or standard medical care. Primary outcome was good functional outcome, defined as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-3 at 365 days, adjusted for group differences in prespecified baseline covariates (stability intracerebral haemorrhage size, age, Glasgow Coma Scale, stability intraventricular haemorrhage size, and clot location). Analysis of the primary efficacy outcome was done in the modified intention-to-treat (mITT) population, which included all eligible, randomly assigned patients who were exposed to treatment. All randomly assigned patients were included in the safety analysis. This study is registered with ClinicalTrials.gov, number NCT01827046. Between Dec 30, 2013, and Aug 15, 2017, 506 patients were randomly allocated: 255 (50%) to the MISTIE group and 251 (50%) to standard medical care. 499 patients (n=250 in the MISTIE group; n=249 in the standard medical care group) received treatment and were included in the mITT analysis set. The mITT primary adjusted efficacy analysis estimated that 45% of patients in the MISTIE group and 41% patients in the standard medical care group had achieved an mRS score of 0-3 at 365 days (adjusted risk difference 4% [95% CI -4 to 12]; p=0·33). Sensitivity analyses of 365-day mRS using generalised ordered logistic regression models adjusted for baseline variables showed that the estimated odds ratios comparing MISTIE with standard medical care for mRS scores higher than 5 versus 5 or less, higher than 4 versus 4 or less, higher than 3 versus 3 or less, and higher than 2 versus 2 or less were 0·60 (p=0·03), 0·84 (p=0·42), 0·87 (p=0·49), and 0·82 (p=0·44), respectively. At 7 days, two (1%) of 255 patients in the MISTIE group and ten (4%) of 251 patients in the standard medical care group had died (p=0·02) and at 30 days, 24 (9%) patients in the MISTIE group and 37 (15%) patients in the standard medical care group had died (p=0·07). The number of patients with symptomatic bleeding and brain bacterial infections was similar between the MISTIE and standard medical care groups (six [2%] of 255 patients vs three [1%] of 251 patients; p=0·33 for symptomatic bleeding; two [1%] of 255 patients vs 0 [0%] of 251 patients; p=0·16 for brain bacterial infections). At 30 days, 76 (30%) of 255 patients in the MISTIE group and 84 (33%) of 251 patients in the standard medical care group had one or more serious adverse event, and the difference in number of serious adverse events between the groups was statistically significant (p=0·012). For moderate to large intracerebral haemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral haemorrhage. The procedure was safely adopted by our sample of surgeons. National Institute of Neurological Disorders and Stroke and Genentech. [Abstract copyright: Copyright © 2019 Elsevier Ltd. All rights reserved.

Parent-Led Activity and Nutrition (plan) for Healthy Living: Design and Methods

Child obesity has become an important public health concern, especially in rural areas. Primary care providers are well positioned to intervene with children and their parents, but encounter many barriers to addressing child overweight and obesity. This paper describes the design and methods of a cluster-randomized controlled trial to evaluate a parent-mediated approach utilizing physician\u27s brief motivational interviewing and parent group sessions to treat child (ages 5–11 years) overweight and obesity in the primary care setting in Southern Appalachia. Specific aims of this pilot project will be 1) to establish a primary care based and parent-mediated childhood overweight intervention program in the primary care setting, 2) to explore the efficacy of this intervention in promoting healthier weight status and health behaviors of children, and 3) to examine the acceptability and feasibility of the approach among parents and primary care providers. If proven to be effective, this approach may be an exportable model to other primary care practices

Chromosomal aberrations in resident small mammals at a petrochemical waste dump site : a natural model for analysis of environmental mutagenesis

Typescript (photocopy).Small mammals of two species (Peromyscus leucopus and Sigmodon hispidus) were trapped at a locality polluted with a complex mixture of petrochemical waste products, heavy metals, and PCB's, and from two matched, uncontaminated localities. Three cytogenetic techniques were employed to evaluate the use of these resident small mammals as indicators of environmental mutagenesis. Each technique also was assessed for its power of resolution in characterizing the action of environmental mutagens. Standard karyological analysis of flow cytometric analysis clearly indicated significant differences in chromosomal aberrancy between animals collected at the polluted site and the uncontaminated sites. Standard karyology showed increases in lesions per cell and aberrant cells per individual for both species at the polluted site. Peromyscus apparently was more susceptible to chromosomal aberration than Sigmodon at both the polluted site and one control site. Examination of flow DNA histograms of Peromyscus from the polluted site revealed broadened and flattened G1 peaks and increases in CVs (coefficients of variation) for DNA content. CVs in animals from the polluted site consistently fell outside confidence limits set around values from animals collected at the uncontaminated site. These patterns are characteristically seen in laboratory animals challenged with powerful clastogens which suggests that individuals at the polluted site may be experiencing similar clastogenic events. G-band karyological analysis did not reveal significant differences in aberrancy between the polluted site and the control sites but did indicate that unique responses occur in individual chromosomes. Two chromosomes (5, 21) were found to be exceptionally susceptible to rearrangement. Several classes of aberrations not detectable in standard karyotypes also were observed in G-band karyotypes. This study demonstrates that small mammals are a feasible test model for evaluating environmental mutagenesis. Evaluation of different cytogenetic techniques suggests that a battery of several assays will provide the most accurate characterization of the action of environmental mutagenesis

Robert James Baker (1942-2018), Obituary

First paragraph: On 30 March 2018, the science of mammalogy and the American Society of Mammalogists lost one of the most influential figures of the last half-century. Robert James Baker died quietly at his home in Lubbock, Texas (Fig. 1). He was born on 8 April 1942 to James Simeon Baker and Laura Cooper in Warren, Arkansas. His father was killed during World War II and his mother remarried, resulting in his growing up with six half-siblings. According to Robert’s autobiography in Going afield (330—number refers to specific publication in “Bibliography”), he spent a good deal of his youth with his grandparents on a 100-acre farm in the West Gulf Coastal Plain of southeastern Arkansas. He identified his maternal grandmother, “Grandma Rosie,” as his best friend and his greatest influence during these years. His marriage to Jean Joyner on 19 August 1961 ended in divorce in 1975, but the marriage resulted in a daughter, April Baker-Padilla, and two grandchildren, Jason Baker and Faith Padilla. Robert was married to his wife of 39 years, Laura Kyle (M.D.), on 28 May 1978 in Lubbock. Their son, Robert Kyle Baker, preceded his father in death, which was a tragedy from which neither Robert nor Laura ever completely recovered